| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| 10mg | |||
| Other Sizes |
| Targets |
Wnt signaling[1]
YB-0158 targets the interaction between Sam68 (Src-associated in mitosis 68 kDa protein) and Src, a non-receptor tyrosine kinase. By disrupting Sam68-Src interactions, the compound inhibits downstream signaling pathways, including the Wnt pathway. The Wnt signaling pathway is critically involved in colorectal cancer stem cell maintenance and proliferation. By targeting this pathway, YB-0158 effectively eliminates cancer stem cells and induces apoptosis in colorectal cancer cells. The compound's mechanism of action involves the disruption of protein-protein interactions essential for CSC survival. |
|---|---|
| ln Vitro |
YB-0158 (0.2 μM and 0.5 μM; 48 hours) dramatically promotes CRC cell apoptosis, as shown by assays for the detection of active Caspase-3/7[1]. Comparing YB-0158 (0.3 μM) to DMSO control, there is a comparable decrease in CBP recruitment at the promoter of Wnt/beta-Catenin target genes LGR5 and MYC in HT29 cells[1].
In vitro studies demonstrate that YB-0158 is a potent colorectal cancer stem cell targeting agent. At concentrations of 0.2 microM and 0.5 microM, the compound dramatically promotes apoptosis in colorectal cancer cells, as shown by assays for the detection of active Caspase-3/7. The compound's anti-cancer activity is attributed to its ability to disrupt Sam68-Src interactions and inhibit Wnt signaling. Its potency against cancer stem cells suggests it may be effective against tumor recurrence and metastasis. The compound's in vitro activity is typically assessed using colorectal cancer cell lines and cancer stem cell enrichment cultures. |
| ln Vivo |
In MC38 cells grown, YB-0158 has an EC50 of 1.64 μM. No discernible variations in primary tumor size are observed between saline controls and YB-0158 (100 mg/kg; IP; C57BL/6 mice carrying MC38 cells) in vivo treatments[2].
In vivo activity of YB-0158 has not been extensively characterized in the literature, though its potent in vitro activity against colorectal cancer cells suggests potential in vivo efficacy. As a Wnt pathway inhibitor and cancer stem cell targeting agent, the compound has potential applications in colorectal cancer therapy, particularly for targeting the CSC population responsible for tumor recurrence. However, specific in vivo efficacy data, including tumor growth inhibition in xenograft models, are not reported in the available literature. The compound is primarily used as a research tool for studying Wnt signaling and cancer stem cell biology. |
| Enzyme Assay |
In vitro enzyme/receptor binding assays for YB-0158 focus on measuring its ability to disrupt Sam68-Src interactions. The assay typically uses purified recombinant Sam68 and Src proteins or immunoprecipitation from cell lysates. Co-immunoprecipitation experiments are performed to assess the compound's ability to reduce Sam68-Src binding in treated cells. Alternatively, surface plasmon resonance (SPR) or fluorescence polarization assays can be used to measure the binding affinity of the compound for Sam68 or Src. The compound's inhibition of Wnt signaling is confirmed by measuring the expression of Wnt target genes (e.g., c-Myc, Cyclin D1) by qPCR or Western blotting.
|
| Cell Assay |
Cellular assays for YB-0158 are conducted using colorectal cancer cell lines to evaluate its anti-proliferative and pro-apoptotic effects. Cells are treated with the compound at concentrations of 0.2 microM and 0.5 microM for 48 hours. Apoptosis is assessed by measuring active Caspase-3/7 activity using fluorogenic substrates, flow cytometry with Annexin V/PI staining, or TUNEL assays. Cell viability is measured using MTT or similar assays. The compound's effects on cancer stem cell populations are evaluated using sphere formation assays or by measuring the expression of CSC markers (e.g., CD133, CD44, LGR5).
|
| Animal Protocol |
In vivo animal studies for YB-0158 are limited, as the compound is primarily used as a research tool. For in vivo efficacy studies, xenograft models using colorectal cancer cell lines could be employed. Tumor-bearing mice would be treated with the compound via intraperitoneal or oral administration at various doses. Tumor volume would be measured regularly, and body weight monitored for tolerability. At study termination, tumors would be analyzed for apoptosis markers (Caspase-3/7), Sam68-Src interaction status, Wnt target gene expression, and CSC marker expression. However, specific in vivo study protocols and results are not extensively reported in the available literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of YB-0158 have not been extensively characterized in the literature. The compound is a reverse-turn peptidomimetic, suggesting it may have improved stability and bioavailability compared to linear peptides. The compound's molecular weight and formula are not specified in the available search results. Detailed PK parameters such as half-life, volume of distribution, and bioavailability are not reported. The compound's physicochemical properties suggest it could be formulated for in vivo administration using standard approaches, though specific formulation data are not available. The compound is typically stored at -20degC.
|
| Toxicity/Toxicokinetics |
Toxicological data for YB-0158 are limited, as the compound is used primarily as a research tool rather than a therapeutic agent. The compound is not intended for human therapeutic use and is supplied for research purposes only. In cell-based assays, the compound induces apoptosis in colorectal cancer cells at concentrations of 0.2-0.5 microM, suggesting potent anti-cancer activity with potential cytotoxicity. Higher concentrations may cause non-specific effects. Standard safety precautions should be followed when handling this compound. Specific toxicity profiles in animal models are not reported in the available literature.
|
| References | |
| Additional Infomation |
YB-0158 (Wnt pathway inhibitor 2) is a potent colorectal cancer stem cell targeting agent that disrupts Sam68-Src interactions and induces apoptosis in colorectal cancer cells. It is a reverse-turn peptidomimetic with significant anti-cancer activity. By inhibiting Wnt signaling, the compound effectively targets cancer stem cells. The compound has potential applications in colorectal cancer therapy. It is not an FDA-approved drug and has no clinical indications. The compound is available in high purity (≥99.80%) and is typically stored at -20degC.
|
| Molecular Formula |
C32H32N7NA2O7P
|
|---|---|
| Molecular Weight |
703.592489242554
|
| Exact Mass |
703.189
|
| CAS # |
1144043-83-3
|
| PubChem CID |
90301078
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
49
|
| Complexity |
1180
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
P(=O)([O-])([O-])OC1C=CC(=CC=1)C[C@H]1C(N(CC2C=CC=C3C=NNC=23)C[C@@H]2N(C(NCC3C=CC=CC=3)=O)N(CC=C)CC(N21)=O)=O.[Na+].[Na+]
|
| InChi Key |
BUCIVAHDHKFRLG-QLBXQKMFSA-L
|
| InChi Code |
InChI=1S/C32H34N7O7P.2Na/c1-2-15-37-21-29(40)38-27(16-22-11-13-26(14-12-22)46-47(43,44)45)31(41)36(19-25-10-6-9-24-18-34-35-30(24)25)20-28(38)39(37)32(42)33-17-23-7-4-3-5-8-23;;/h2-14,18,27-28H,1,15-17,19-21H2,(H,33,42)(H,34,35)(H2,43,44,45);;/q;2*+1/p-2/t27-,28-;;/m0../s1
|
| Chemical Name |
disodium;[4-[[(6S,9aS)-1-(benzylcarbamoyl)-8-(1H-indazol-7-ylmethyl)-4,7-dioxo-2-prop-2-enyl-3,6,9,9a-tetrahydropyrazino[2,1-c][1,2,4]triazin-6-yl]methyl]phenyl] phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (142.13 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.55 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.55 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.55 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4213 mL | 7.1064 mL | 14.2128 mL | |
| 5 mM | 0.2843 mL | 1.4213 mL | 2.8426 mL | |
| 10 mM | 0.1421 mL | 0.7106 mL | 1.4213 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
